Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gils

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Biochimica Et Biophysica Acta|December 22, 1999
The importance of helix F in plasminogen activator inhibitor-1N Vleugels, A Gils, A P Bijnens, et al.
Journal of Thrombosis and Haemostasis : JTH|February 26, 2010
Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitorK Buelens, G Hassanzadeh-Ghassabeh, S Muyldermans, et al.
Journal of Thrombosis and Haemostasis : JTH|January 21, 2012
Convalescent plasma levels of TAFI activation peptide predict death and recurrent vascular events in ischemic stroke survivorsK Jood, P Redfors, A Gils, et al.
Journal of Thrombosis and Haemostasis : JTH|September 28, 2006
Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI)--a comparative study assessing the biological equivalence of rat, murine and human TAFIK Hillmayer, A Macovei, D Pauwels, et al.
Journal of Thrombosis and Haemostasis : JTH|January 27, 2005
TAFI levels in patients with acute myocardial infarction treated with thrombolysisC Frere, S Renard, A Gils, et al.
The Journal of Biological Chemistry|February 29, 2000
Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodiesA P Bijnens, A Gils, I Knockaert, et al.
Journal of Thrombosis and Haemostasis : JTH|April 14, 2012
Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysisN Mishra, K Buelens, S Theyskens, et al.
Journal of Thrombosis and Haemostasis : JTH|August 30, 2008
Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitorK Hillmayer, R Vancraenenbroeck, M De Maeyer, et al.
Biochemical and Biophysical Research Communications|August 2, 2003
Structural determinants in the stability of the serpin/proteinase complexB De Taeye, K Verbeke, G Compernolle, et al.
Gut|February 19, 2011
Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatmentN Vande Casteele, V Ballet, G Van Assche, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Biochimica Et Biophysica Acta|December 22, 1999
The importance of helix F in plasminogen activator inhibitor-1N Vleugels, A Gils, A P Bijnens, et al.
Journal of Thrombosis and Haemostasis : JTH|February 26, 2010
Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitorK Buelens, G Hassanzadeh-Ghassabeh, S Muyldermans, et al.
Journal of Thrombosis and Haemostasis : JTH|January 21, 2012
Convalescent plasma levels of TAFI activation peptide predict death and recurrent vascular events in ischemic stroke survivorsK Jood, P Redfors, A Gils, et al.
Journal of Thrombosis and Haemostasis : JTH|September 28, 2006
Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI)--a comparative study assessing the biological equivalence of rat, murine and human TAFIK Hillmayer, A Macovei, D Pauwels, et al.
Journal of Thrombosis and Haemostasis : JTH|January 27, 2005
TAFI levels in patients with acute myocardial infarction treated with thrombolysisC Frere, S Renard, A Gils, et al.
The Journal of Biological Chemistry|February 29, 2000
Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodiesA P Bijnens, A Gils, I Knockaert, et al.
Journal of Thrombosis and Haemostasis : JTH|April 14, 2012
Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysisN Mishra, K Buelens, S Theyskens, et al.
Journal of Thrombosis and Haemostasis : JTH|August 30, 2008
Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitorK Hillmayer, R Vancraenenbroeck, M De Maeyer, et al.
Biochemical and Biophysical Research Communications|August 2, 2003
Structural determinants in the stability of the serpin/proteinase complexB De Taeye, K Verbeke, G Compernolle, et al.
Gut|February 19, 2011
Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatmentN Vande Casteele, V Ballet, G Van Assche, et al.
Pageof 6